Efficacy and Safety of Peginterferon in ET and PV.
This is a single-arm, single-center study aims to recruit 40 participants with Essential Thrombocythemia (ET) and Polycythemia Vera (PV). Eligible participants will receive a subcutaneous injection of Peginterferon α-2b 180 mcg once a week and follow-up，and efficacy and safety will be evaluated.
Essential Thrombocythemia|Polycythemia Vera
DRUG: Peginterferon α-2b injection
Hematologic remission rate, Week 12,24
Molecular remission rate, Week 24,48|Peripheral blood driver genes, Week 24,48|Bone marrow-driven genes, Week 24,48|The incidence of thrombosis, Week 24,48|Incidence of bleeding events, Week 24,48|The incidence of progression to myelofibrosis., Week 24,48|The incidence of acute leukemia., Week 24,48|Changes in the burden of driver gene mutations during maintenance therapy., Week 24,48|Hematologic remission, Week 48|Spleen enlargement remission rate., Week 24,48
This is a single-arm, single-center study aims to recruit 40 participants with Essential Thrombocythemia (ET) and Polycythemia Vera (PV). Eligible participants will receive a subcutaneous injection of Peginterferon α-2b 180 mcg once a week and follow-up，and efficacy and safety will be evaluated.